Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.310 +0.130 (+4.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,577,754
Open 3.270
Bid (Size) 3.320 (100)
Ask (Size) 3.330 (9,100)
Prev. Close 3.180
Today's Range 3.210 - 3.360
52wk Range 2.770 - 7.180
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire

Performance

YTD
-21.2%
-21.2%
1 Month
-16.4%
-16.4%
3 Month
-1.8%
-1.8%
6 Month
-19.3%
-19.3%
1 Year
-42.9%
-42.9%

More News

Read More
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
Via The Motley Fool
Topics Workforce
News headline image
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗
Via Chartmill
News headline image
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Via The Motley Fool
Topics ETFs
News headline image
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗
Via MarketBeat
Topics Artificial Intelligence Economy Regulatory Compliance
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Reports First Quarter Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces Board Transition
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.310
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 08/04/26 04:00 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 557.49M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 557M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.